Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life

Introduction:This study aimed to analyze the survivaloutcomes and adverse events (AEs) associated with thelong-term use of tyrosine kinase inhibitors (TKIs) and toassess health-related quality of life (HRQoL) in patients withchronic myeloid leukemia (CML).Methods:Medical recordsof 345 patients with CML treated with at least one type of TKIwere retrospectively reviewed.Results:No significant dif-ferences in survival were observed based on the number ofdifferent TKIs the patients received (p= 0.301) or the se-quence of TKIs used (p= 0.770). Among 182 patients treatedwith nilotinib, 25 experienced cardiovascular events (CVEs).After 10 years of nilotinib treatment, CVEs occurred in 55.2%of patients with >= 2 vascular risk factors. Pleural effusion wasobserved in 27 of 78 dasatinib-treated patients. In terms ofHRQoL, patients treated with nilotinib generally reportedhigher satisfaction levels than did those treated with im-atinib or dasatinib. When stratified by age or duration of TKItreatment, patients aged<60 years or those with a treat-ment duration of >= 1 year exhibited better satisfaction levels.Conclusion:Survival outcomes were not affected by historyof TKI treatment. Nilotinib is favorable for HRQoL but in-creases the risk of serious CVEs in patients with vascular riskfactors.(c) 2025 S. Karger AG, Basel